Key insights
- Twist Bioscience's COO sold shares to cover tax obligations, a non-discretionary event. Despite a revenue beat in Q2 2026, EPS missed expectations. TD Cowen raised its price target, but InvestingPro suggests the stock is overvalued. Overall, the news presents a mixed signal with limited negative influence on the broader US market.
Patrick John Finn, President and Chief Operating Officer of Twist Bioscience Corp (NASDAQ:TWST), sold 2,844 shares of the company’s common stock on May 4, 2026. The transaction totaled approximately $162,531.
The shares were sold at a price of $57.1488 per share. The stock has since risen to $59.53, reflecting a strong 73% gain over the past year.
These sales were executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units. The company’s equity incentive plans mandate that such tax obligations be satisfied through a "sell to cover" transaction, indicating these were not discretionary trades by Mr. Finn.
Following this transaction, Mr. Finn directly owns 278,964 shares of Twist Bioscience common stock.According to InvestingPro analysis, TWST appears overvalued at current levels and trades with high volatility (Beta: 2.23). Investors can access the comprehensive Pro Research Report for deeper insights into the company’s valuation and growth prospects.
In other recent news, Twist Bioscience reported its second-quarter earnings for fiscal year 2026, highlighting a strong revenue performance. The company achieved total revenues of $111 million, marking a 19% increase compared to the previous year and surpassing the consensus estimate of $108 million. However, the earnings per share (EPS) fell short of expectations, with Twist Bioscience reporting an EPS of -$0.71, compared to the forecasted -$0.48. Despite this earnings miss, the company’s stock experienced a rise in pre-market trading, indicating investor optimism about its revenue growth.
Additionally, TD Cowen responded to these developments by raising its price target for Twist Bioscience stock from $58 to $68, while maintaining a Buy rating. The firm’s decision was influenced by the company’s revenue beat, which outperformed market expectations. These recent developments suggest a mixed but cautiously positive outlook for Twist Bioscience, as reflected in analyst actions and investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.